Daily Sepsis Research Analysis
Analyzed 40 papers and selected 3 impactful papers.
Summary
Three impactful studies advance sepsis science today: an FDA-approved antifungal, ciclopirox olamine, is repurposed as a direct NLRP3 inflammasome inhibitor with efficacy in murine sepsis; a Blood paper uncovers a TGFβ–PD‑L1 checkpoint in neutrophils that preserves lung barrier integrity during hyperinflammation; and a multicenter prospective cohort shows immune biomarkers markedly improve early prediction of sepsis‑associated acute kidney injury in older adults.
Research Themes
- Innate immune modulation and inflammasome targeting
- Neutrophil immune checkpoints balancing host defense and tissue protection
- Risk stratification of sepsis-associated acute kidney injury using immune biomarkers
Selected Articles
1. Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases.
This study identifies ciclopirox olamine as a direct, selective NLRP3 inflammasome inhibitor that binds the NACHT domain (Y381), reduces ATPase activity, and blocks oligomerization. CPX demonstrated therapeutic efficacy in murine sepsis, with additional benefits in colitis and metabolic models, and showed activity ex vivo in human cells.
Impact: Provides a drug-repurposing route with a defined molecular mechanism to target a central inflammatory driver relevant to sepsis. The mechanistic specificity and in vivo efficacy substantially advance translational potential.
Clinical Implications: Although preclinical, CPX could be rapidly advanced into early-phase trials for NLRP3-driven conditions including sepsis. Dosing, pharmacokinetics, and safety for systemic use require rigorous evaluation before clinical adoption.
Key Findings
- Ciclopirox selectively inhibited NLRP3 inflammasome activation without affecting AIM2, NLRC4, Pyrin, NLRP1, or NLRP6.
- CPX bound the NLRP3 NACHT domain at Y381, reduced ATPase activity, and blocked NLRP3 oligomerization and assembly.
- Therapeutic administration improved outcomes in mouse models of LPS-induced sepsis and was active ex vivo in human cells, including from gout patients.
Methodological Strengths
- Mechanistic mapping including target engagement at a defined residue (Y381) with functional ATPase assays
- Demonstrated specificity across multiple inflammasome platforms and efficacy in multiple in vivo disease models
Limitations
- Evidence is preclinical; systemic dosing, pharmacokinetics, and safety of CPX for sepsis are not established
- Potential off-target effects and species differences in NLRP3 binding require further study
Future Directions: Perform dose-ranging, PK/PD, and safety studies for systemic CPX; validate efficacy in polymicrobial sepsis (e.g., CLP) and human primary immune cells; explore structure-guided optimization of NACHT-binding derivatives.
The aberrant activation of the NOD-like receptor protein 3 (NLRP3) inflammasome has been implicated in the pathogenesis of various human inflammatory diseases. Although a wide variety of NLRP3 inflammasome inhibitors have been developed, no drug targeting the NLRP3 inflammasome has been approved for use in clinical settings. In this study, we identified ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), as a novel NLRP3 inflammasome inhibitor. CPX specifically blocks NLRP3 inflammasome activation but not AIM2, NLRC4, Pyrin, NLRP1, or NLRP6 inflammasomes. Mechanistically, CPX directly disturbs NLRP3 inflammasome assembly by inhibiting NLRP3 oligomerization. Furthermore, CPX binds to the NACHT domain of NLRP3 at Y381 and reduces NLRP3 ATPase activity, thereby blocking NLRP3 oligomerization. More importantly, CPX administration notably exerts therapeutic effects on mouse models of sepsis, colitis, and metabolic disorders. CPX is also active ex vivo in cells from healthy individuals or patients with gout. Taken together, our results demonstrate that CPX acts as an NLRP3 inflammasome inhibitor and is a promising therapeutic agent for NLRP3 inflammasome-associated diseases.
2. TGFβ-PDL1 signaling in neutrophils preserves lung barrier during hyperinflammation.
A TGFβ–PD‑L1 axis in neutrophils functions as an immune checkpoint that limits pathogenic hyperactivation during cytokine storm, preserving lung barrier integrity while maintaining host defense. Neutrophil-specific PD‑L1 deletion disrupted intravascular clustering and exacerbated tissue infiltration, but restored trafficking to infection foci.
Impact: Reveals a previously unappreciated neutrophil checkpoint that balances host defense with tissue protection, offering a mechanistic basis for immunomodulation in sepsis and trauma.
Clinical Implications: Targeting the TGFβ–PD‑L1 axis on neutrophils may enable precision control of hyperinflammation without compromising antimicrobial defense, informing future therapeutic strategies in sepsis and acute lung injury.
Key Findings
- TGFβ signaling upregulates PD‑L1 on neutrophils and modulates activation during hyperinflammatory states.
- Disrupting TGFβ signaling restored neutrophil migration but caused excessive activation, severe pulmonary damage, and increased spontaneous lung bacterial infection.
- Neutrophil PD‑L1 promoted intravascular clustering and limited tissue infiltration; neutrophil-specific PD‑L1 deletion reversed clustering and altered trafficking.
Methodological Strengths
- Multiple murine hyperinflammation models with cell-type–specific genetic deletion
- Mechanistic dissection of neutrophil behavior in lung microcirculation
Limitations
- Findings are in murine models; human validation and translational dosing windows are unknown
- Potential trade-offs between barrier protection and antimicrobial trafficking require careful balancing in therapy
Future Directions: Validate the TGFβ–PD‑L1 axis in human sepsis cohorts and lung tissues; explore pharmacologic modulation of neutrophil PD‑L1; define therapeutic windows that optimize defense and limit injury.
The hyperinflammatory syndromes in critically ill patients, including trauma, sepsis, and acute lung injury, are characterized by dysregulated neutrophil responses that contribute to tissue damage and poor outcomes. Using murine models of cytokine storm induced by trauma and lung injury, we identified transforming growth factor β (TGFβ) as a central regulator of immune checkpoint in neutrophils. TGFβ signaling modulates neutrophil activation and upregulates the expression of programmed death-ligand 1 (PDL1). Disruption of TGFβ signaling during hyperinflammation restores the migratory capacity of neutrophils but leads to excessive activation, severe pulmonary tissue damage, and increased susceptibility to spontaneous bacterial infection in the lung. Mechanistically, PDL1 expression alters neutrophil behavior within lung capillaries, promoting intravascular clustering and restricting tissue infiltration. Targeted deletion of PDL1 in neutrophils reverses hyperinflammation-induced clustering, restores effective trafficking to infectious foci, and enhances host-protective immune function while limiting pathological neutrophil hyperactivation. These findings define a TGFβ-PDL1 regulatory axis that restrains the pathogenicity of neutrophils during hyperinflammation, revealing a checkpoint mechanism that balances host defense and tissue integrity.
3. Immunoinflammatory biomarkers for sepsis-associated acute kidney injury: a multicenter prospective cohort study.
In 627 older adults with sepsis, integrating complement (C3, C4) and lymphocyte subset measures (CD4% T cells, NK cells) with clinical variables markedly improved early SA-AKI prediction (AUC 0.878 vs. 0.717). Results support targeted immune monitoring to individualize risk assessment.
Impact: Offers actionable biomarkers and a validated model that outperform clinical variables alone for early SA-AKI prediction in a high-risk, under-studied older population.
Clinical Implications: Incorporating complement and lymphocyte subset testing at ICU admission may enhance early SA-AKI risk stratification and guide monitoring and renoprotective strategies in older adults with sepsis.
Key Findings
- Integrated model including C3, C4, CD4% T cells, and NK cells achieved AUC 0.878 versus 0.717 for the clinical model (p < 0.001).
- Net reclassification improvement of 86.1% (p = 0.002) with immune biomarkers added.
- SA-AKI incidence was 43.1% among 627 older adults in Beijing ICUs with data collected within 24 hours.
Methodological Strengths
- Prospective multicenter cohort with early (≤24 h) biomarker assessment
- Model development with ten-fold cross-validation and internal test set evaluation
Limitations
- Internal validation only; external generalizability beyond Beijing ICUs and to non-older adults is unknown
- Observational design; no interventional testing of biomarker-guided strategies
Future Directions: Externally validate the model across diverse health systems and age groups; assess clinical utility via impact studies testing biomarker-guided renoprotective interventions.
BACKGROUND: Immune dysregulation is central to sepsis-related organ injury, yet standard clinical indicators show limited predictive value for sepsis-associated acute kidney injury (SA-AKI) in older adults(aged ≥ 65 years). This study evaluated whether immuno-inflammatory biomarkers improve early prediction of SA-AKI. METHODS: In this prospective multicenter cohort of 627 older adults with sepsis admitted to ICUs in five Beijing tertiary hospitals, the overall incidence of SA-AKI was 43.1% (270/627). Clinical variables and immune-inflammatory markers collected within 24 h were used to construct a clinical model (Model 1) and an integrated model (Model 2, combining clinical variables with immuno-inflammatory biomarkers). Model performance was examined using ten-fold cross-validation and an internal test set. RESULTS: Six clinical predictors were included in Model 1, while Model 2 additionally incorporated C3, C4, CD4% T cells, and NK cells. In the testing set, Model 2 showed markedly better discrimination than Model 1 (AUC 0.878 vs. 0.717; p < 0.001) with higher sensitivity and specificity. Immune-marker inclusion significantly improved risk reclassification (NRI 86.1%; p = 0.002). CONCLUSIONS: Adding immuno-inflammatory biomarkers substantially enhanced early prediction of SA-AKI in older adults, underscoring the key role of immune imbalance and supporting targeted immune monitoring for individualized risk assessment.